James Witek

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Paul Y. Kwo, Norman Gitlin, Ronald Nahass et al. · Hepatology · 2016 · 189 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Eric Lawitz, Gary Matusow, Edwin DeJesus et al. · Hepatology · 2015 · 180 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Increased CD95/Fas-Induced Apoptosis of HIV-Specific CD8+ T Cells

Yvonne M. Mueller, Stephen C. De Rosa, Justin A Hutton et al. · Immunity · 2001 · 165 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14

IL-15 enhances survival and function of HIV-specific CD8+ T cells

Yvonne M. Mueller, Paul Bojczuk, E. Scott Halstead et al. · Blood · 2003 · 134 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

Christine Katlama, Bonaventura Clotet, Anthony Mills et al. · Antiviral Therapy · 2010 · 102 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17